• Recurrence of Kidney Inflammation a Risk Factor for Kidney Rejection After Transplant, Study Shows
  • ‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
  • #ECRD2018 – EU Must Do More for Rare Disease Patients, Eurordis Leaders Say
  • Severe Alport Mutations Do Not Affect Kidney Transplant Outcomes, Study Shows
  • Article Questioning Safety of Phase 3 Bardoxolone Trial ‘Inaccurate,’ Reata CMO Says
  • #ECRD2018 – Patient Access and Collaboration Focus of Eurordis Meeting May 10-12
  • Experts Raise Concerns Over Bardoxolone’s Long-term Safety in Alport Patients
  • Variations Between Alport, Pierson Syndromes Explain Kidney Damage Differences
  • Bardoxolone Methyl Continues to Aid Alport Patients with Kidney Disease, New Data Shows
  • NIH Agency Pioneers Collaborative Research into Rare Diseases
  • Researchers Find Potential Therapeutic Target for Alport Syndrome in Mouse Study
  • New System Proposed for Classifying Collagen IV Gene Disorders as Types of Alport